A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males

Sponsor
The United Bio-Technology (Hengqin) Co., Ltd.
Study ID
NCT07630233
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Eligibility Criteria

Sex
MALE
Age
18 Years - 45 Years
Healthy Volunteers
Accepted

Interventions

  • UBT38006 — DRUG
    Ascending single doses - 4 dose levels
  • Placebo — DRUG
    Ascending single doses - 4 dose levels
  • Insulin Degludec Injection — DRUG
    single subcutaneous injection
  • Insulin Icodec Injection — DRUG
    single subcutaneous injection

Study Details

This study is a single-center, randomized, double-blind, placebo- and active-controlled, parallel-group, single-ascending dose (SAD) design. Insulin degludec and insulin icodec injection serves as the active control and is administered in an open-label manner. The study will be conducted across 6 cohorts, comprising 4 dose-escalation cohorts of UBT38006 (1, 3, 6, and 12 nmol/kg) ， 1 active control cohort of insulin degludec (0.4 U/kg \[2.4 nmol/kg\]) and 1 active control cohort of insulin icodec (1.25 U/kg \[7.5 nmol/kg\]). The safety and tolerability (including local tolerability) as well as the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single subcutaneous doses of UBT38006 injection will be evaluated in healthy adult male participants. In Cohort 1 (1 nmol/kg), participants will be randomized in a 4:1 ratio to receive UBT38006 injection or placebo. In Cohorts 2-4 (3, 6, and 12 nmol/kg), participants will be randomized in an 8:2 ratio to receive the corresponding dose of UBT38006 injection or placebo. Participants in Cohort 5 (insulin degludec active control) will receive 0.4 U/kg (2.4 nmol/kg) insulin degludec injection. Participants in the insulin icodec cohort received a subcutaneous injection of insulin icodec at a dose of 1.25 U/kg(7.5 nmol/kg). Cohorts 1-4 will follow a double-blind design, while Cohort 5 and insulin icodec cohort will be open-label.

Key Dates

First listed
Jun 5, 2026
Start date
Jun 19, 2026
Status verified
Jul 2026
Primary completion
Oct 25, 2026
Completion
Oct 25, 2026

Study Design

Enrollment
53 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: UBT38006
    s.c, single dose
  • Placebo Comparator: Placebo
    s.c, single dose
  • Active Comparator: Insulin Degludec Active Control
    0.4U/kg Insulin Degludec Injection，single subcutaneous injection
  • Active Comparator: Insulin Icodec Active Control
    1.25U/kg Insulin icodec Injection，single subcutaneous injection

Primary Outcome Measure

incidence of adverse events (AEs), adverse drug reactions (ADRs), serious adverse events (SAEs), etc,.. [ Time Frame: Baseline to Day43 ]

Central Contacts

Related Studies